TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452, an innovative anti-COVID-19 vaccine
01 sept. 2020 12h41 HE
|
Akston Biosciences
BEVERLY, Mass., USA & GRONINGEN, the Netherlands, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Today, TRACER Europe B.V. (“TRACER”), a Clinical Research Organization (CRO) specializing in fast-track...
First Patient Treated in Phase 1 Clinical Trial Of Incysus Therapeutics Gamma Delta (γδ) T Cell Immunotherapy for Patients With Newly Diagnosed Glioblastoma
02 juin 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Treats First Patient in Phase 1 Study of Gamma Delta (γδ) T Cell Immunotherapy in Leukemia and Lymphoma Patients Undergoing Allogeneic Stem Cell Transplantation
12 mai 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
INCYSUS THERAPEUTICS TO PRESENT AT THE 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE
06 avr. 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
INCYSUS THERAPEUTICS TO PRESENT AT THE NYC SPRING ONCOLOGY INVESTOR CONFERENCE
31 mars 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
Incysus Therapeutics Initiates Enrollment in Phase 1 Study of a Genetically Modified Gamma-Delta (γδ) T Cell Immunotherapy in Patients with Newly Diagnosed Glioblastoma
27 févr. 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
21 nov. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society
05 sept. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Dual mechanisms, rapid absorption and long half-life support therapeutic potential of AXS-07 in migraine AXS-07 MOMENTUM Phase 3 trial ongoing in migraine patients with history of inadequate response...
Incysus Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference
04 sept. 2019 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Appoints Rozanna Yaing As Senior Vice President, Quality And Regulatory Affairs
02 juil. 2019 08h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...